KLI

검색

Ulsan Univ. Repository

Browsing by 저자 : Byoung Chul Cho

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

가 나 다 라 마 바 사 아 자 차 카 타 파 하

또는 첫 단어:

정렬 기준:
정렬:
결과 수
저자 수

전체 결과 16건 중 1-16 번을 표시중입니다.

1 Article A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors Byoung Chul Cho ; Ji-Youn Han ; Sang-We Kim ; et al 2022
2 Article A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data Parneet Cheema ; Byoung Chul Cho ; Helano Freitas ; et al 2023
3 Article Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study 김상위 ; Amy Roshak ; Byoung Chul Cho ; et al 2021
4 Article Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions Caicun Zhou ; Ke-Jing Tang ; Byoung Chul Cho ; et al 2023
5 Article Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial Byoung Chul Cho ; Dong-Wan Kim ; Alexander I Spira ; et al 2023
6 Article Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer 이대호 ; Adnan Nagrial ; Byoung Chul Cho ; et al 2021
7 Article Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors : A Phase 1a/1b Nonrandomized Controlled Trial Tae Won Kim ; Philippe L. Bedard ; Patricia LoRusso ; et al 2023
8 Article Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial 이대호 ; Byoung Chul Cho ; Chia-Chi Lin ; et al 2020
9 Article Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study Melissa L Johnson ; Byoung Chul Cho ; Alexander Luft ; et al 2023
10 Article Efficacy and Safety of Ceritinib 450 mg/day with Food and 750 mg/day in Fasted State in Treatment-Naïve Patients with ALK+ Non-Small Cell Lung Cancer: Results from the ASCEND-8 Asian Subgroup Analysis Byoung Chul Cho ; Dong-Wan Kim ; Ullas Batra ; et al 2023
11 Article Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study 김상위 ; Anders Mellemgaard ; Byoung Chul Cho ; et al 2020
12 Article Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON) Edward B Garon ; Byoung Chul Cho ; Alexander Luft ; et al 2023
13 Article Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study 이대호 ; Aaron S Mansfield ; Benjamin Besse ; et al 2021
14 Article Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in Korea 김상위 ; Bong-Seog Kim ; Byoung Chul Cho ; et al 2020
15 Article Real-world use of osimertinib in non-small cell lung cancer: ASTRIS study Korean subgroup analysis 김상위 ; Byoung Chul Cho ; Cheol Hyeon Kim ; et al 2020
16 Article Three-Year Follow-Up and Response-Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3) Morihito Okada ; Ken Kato ; Byoung Chul Cho ; et al 2022

OAK Ulsan Univ. Repository는 국립중앙도서관 OAK Repository 보급사업으로 구축되었습니다.